Sajjan India Limited is looking for expansion, both organically and through acquisitions, to achieve the planned growth
This trial is a multi-national, phase 2/3, open-label, randomized, controlled clinical study of utidelone injectable
Collaboration to accelerate and de-risk clinical development of Nanopharmaceutics CNS portfolio
The new range of HDPE bottles is compliant with US FDA, EU regulations and Chinese DMF registration for use in dry pharmaceutical applications
Investment enables development of revolutionary multi-omic platform using super-resolution imaging technology for earlier disease detection and accelerated discovery of therapeutics
Total investments could reach €70 million, of which approximately 15% in R&D and 85% in capex, that would be deployed from 2026
Samsung Biologics will provide Pfizer with additional capacity for large-scale manufacturing for a multi-product biosimilars portfolio
Pfizer is likely to show GSK significant competition
The application is in line with Innocan's strategy to expand the scope of its combined magnesium and cannabis topical solution
UTD2 is the world's first oral epothilone microtubule inhibitor
Subscribe To Our Newsletter & Stay Updated
